Please try another search
© Reuters. FILE PHOTO: Pfizer's coronavirus disease (COVID-19) pill Paxlovid is packaged in Ascoli, Italy, in this undated image obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS
(Reuters) -Pfizer Inc said on Thursday it is seeking full U.S. approval for its oral COVID-19 antiviral treatment Paxlovid, which is currently available under an emergency use authorization (EUA).
Pfizer (NYSE:PFE) said it submitted a New Drug Application for Paxlovid to the Food and Drug Administration for the treatment of COVID-19 in vaccinated and unvaccinated people at high risk of progression to severe illness.
That is basically consistent with the drug's current EUA, which Pfizer said covers 50% to 60% of the U.S. population, citing estimates from the U.S. Centers for Disease Control and Prevention.
A full approval could mean the company would have the option to sell Paxlovid on the open market like other drugs, depending on whether or not the U.S. government decides to stop buying the drug and providing it for free nationwide.
Also, "the company might have more control over educating the public with commercials, or however they want, to boost uptake," said Karen Andersen, healthcare strategist at Morningstar.
The two-drug treatment taken for five days beginning shortly after onset of COVID symptoms reduced the risk of hospitalization or death by 88% in non-hospitalized, high-risk adult patients in Pfizer's clinical trial, which did not included vaccinated people.
Data from a study in Israel earlier this month showed Paxlovid reduced COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, but was not found to prevent severe illness among younger adults.
More than 1.6 million courses of Paxlovid have been administered in the United States, according to data from the Department of Health and Human Services.
By Sheila Dang (Reuters) -Elon Musk's legal team is demanding that Twitter Inc (N:TWTR) turn over the names of employees responsible for calculating what percentage of the...
By Jody Godoy and Michelle Price WASHINGTON (Reuters) -Three former JPMorgan Chase & Co (NYSE:JPM) employees were acquitted of racketeering and conspiracy charges in a landmark...
SAO PAULO (Reuters) -Brazilian pork and poultry processor BRF SA (NYSE:BRFS) on Wednesday reported a second-quarter net loss of 468 million real ($91.86 million), wider than the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.